COGENTIN Drug Patent Profile

« Back to Dashboard

Which patents cover Cogentin, and when can generic versions of Cogentin launch?

Cogentin is a drug marketed by Epic Pharma Llc and Merck and is included in two NDAs.

The generic ingredient in COGENTIN is benztropine mesylate. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the benztropine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cogentin

A generic version of COGENTIN was approved as benztropine mesylate by PLIVA on August 10^th, 1988.

Summary for COGENTIN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Patent Applications:	1,540
Drug Prices:	Drug price information for COGENTIN
What excipients (inactive ingredients) are in COGENTIN?	COGENTIN excipients list
DailyMed Link:	COGENTIN at DailyMed

See drug prices for COGENTIN

Recent Clinical Trials for COGENTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	Phase 2/Phase 3
University of California, San Diego	Phase 2
National Institute of Mental Health (NIMH)	Phase 4

See all COGENTIN clinical trials

US Patents and Regulatory Information for COGENTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	COGENTIN	benztropine mesylate	INJECTABLE;INJECTION	012015-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	COGENTIN	benztropine mesylate	TABLET;ORAL	009193-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	COGENTIN	benztropine mesylate	TABLET;ORAL	009193-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Merck	COGENTIN	benztropine mesylate	TABLET;ORAL	009193-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

COGENTIN (Benztropine) Market Dynamics, Financial Trajectory, Patents and Generic Competition

Last updated: November 10, 2026

Cogentin is the branded form of benztropine mesylate, an anticholinergic drug used primarily to treat drug-induced extrapyramidal symptoms and parkinsonism. Its commercial profile is mature and largely generic. The product has no meaningful remaining regulatory exclusivity, no evident current patent barrier to generic competition, and limited public revenue disclosure. Financial value is concentrated in low-cost generic volume rather than brand pricing power.

What is Cogentin and how is it used?

Cogentin contains benztropine mesylate, a centrally acting anticholinergic. The FDA label identifies two principal uses:

• Treatment of parkinsonism
• Control of extrapyramidal disorders caused by neuroleptic drugs, including phenothiazines and related antipsychotics

Cogentin is available in oral tablets and injectable form. The injection is used when rapid treatment is needed or when oral administration is impractical. The drug does not treat the underlying psychiatric disorder and is not an antipsychotic.

Attribute	Cogentin
Active ingredient	Benztropine mesylate
Drug class	Central anticholinergic
Primary uses	Drug-induced extrapyramidal symptoms; parkinsonism
Dosage forms	Tablets; injection
Regulatory category	Small-molecule prescription drug
Biosimilar pathway	Not applicable
Current market structure	Brand plus multiple generic suppliers
Commercial maturity	Legacy, off-patent product
Public product-level revenue	Not separately disclosed

The FDA label warns about adverse effects associated with anticholinergic activity, including confusion, hallucinations, blurred vision, urinary retention, constipation, tachycardia and heat intolerance. The label also cautions against use in patients with angle-closure glaucoma and emphasizes increased sensitivity among older patients.[1]

When does Cogentin lose exclusivity?

Cogentin lost meaningful market exclusivity decades ago. Benztropine is an established generic active ingredient, and generic versions are sold by multiple manufacturers.

The original product approval dates to the mid-20th century. Any original compound, formulation or use patents associated with the initial development period have expired. Current competition is therefore governed by generic manufacturing capacity, distributor access, pricing and institutional contracts rather than patent exclusivity.

Exclusivity category	Current status
New chemical entity exclusivity	Expired
Original compound patent protection	Expired
Original formulation protection	Expired
Orphan-drug exclusivity	None identified
Pediatric exclusivity	None currently relevant
FDA market exclusivity	None currently relevant
Biosimilar exclusivity	Not applicable
Brand-based protection	Trademark and labeling rights only

The commercial consequence is direct: an ANDA applicant does not need to wait for a current Cogentin patent term to expire before entering the market, assuming FDA approval and compliance with applicable regulatory requirements.

What is the Orange Book status of Cogentin?

The Orange Book is relevant to Cogentin only as a historical reference for the approved brand and any listed patents or exclusivities. No active, commercially material patent barrier is generally associated with the current U.S. benztropine market.

Generic applicants typically rely on an abbreviated new drug application and demonstrate bioequivalence to the reference product. Because the product is an old small molecule with conventional tablet and injectable presentations, development risk is lower than for modified-release drugs, complex injectables or biologics.

The main regulatory issues are likely to involve:

• Bioequivalence for the oral product
• Sterility and manufacturing controls for the injection
• Stability and container-closure compliance
• Accurate anticholinergic safety labeling
• Continued compliance with current good manufacturing practices

The reference-listed-drug status of a legacy product can be operationally more important than patent status. A manufacturer may need to manage supply interruptions, discontinued presentations, or changes in the availability of the reference product even when patent barriers are absent.[2]

How many patents cover Cogentin?

No active patent estate with material blocking power is evident for standard benztropine tablets or injection. The historical patent portfolio would have covered the original active ingredient, pharmaceutical preparations or therapeutic uses, but those rights are no longer commercially significant.

Patent category	Commercial relevance
Benztropine compound patents	Historical; expired
Conventional tablet patents	Historical or expired
Injectable formulation patents	No current blocking estate identified
Drug-induced extrapyramidal symptom use patents	Historical or expired
Manufacturing patents	No known barrier to standard generic production
Device patents	Not central to standard Cogentin presentations

A later patent could theoretically cover a new formulation, delivery system or combination. Such a patent would not automatically block conventional generic tablets or injection unless the claims were broad and enforceable against those products. No widely recognized current patent platform has created a meaningful second-generation exclusivity position for Cogentin.

Which companies are challenging Cogentin, and what is the Paragraph IV risk?

The market is better characterized as an established generic field than as an active Paragraph IV battleground. Paragraph IV litigation is typically most significant when a branded drug has a high-value market, a near-term patent expiry and an active pipeline of ANDA applicants. Cogentin does not fit that profile.

No major current Paragraph IV controversy is central to the commercial outlook for benztropine. Generic entry has already occurred, and the product’s low price reduces the expected value of costly patent litigation.

Potential generic suppliers have included large diversified manufacturers and specialty pharmaceutical companies with established oral solid-dose and injectable capabilities. Supplier participation can vary by national shortage conditions, manufacturing decisions and distributor contracts.

What generic launch scenarios exist?

The plausible U.S. scenarios are:

1. Continued multi-source generic supply with low prices.
2. Temporary price increases during manufacturing shortages.
3. Consolidation if manufacturers exit a low-margin product.
4. Contract-driven substitution among approved generic suppliers.
5. Limited brand retention in institutions that prefer the original label or a specific injectable source.

A new entrant would face little patent risk but could face weak economics. Low reimbursement and established competitors limit the achievable price premium. Injectable manufacturing adds more compliance risk than tablets because sterile production failures can produce shortages and recalls.

What formulations are protected by Cogentin patents?

No current formulation patent is known to create material exclusivity for standard Cogentin tablets or injection. The commercial formulation profile is relatively simple:

• Oral tablets containing benztropine mesylate
• Injectable solution containing benztropine mesylate

The injection is more difficult to manufacture than the tablet because of sterility, particulate control, container integrity and validated aseptic processing. Those requirements are manufacturing barriers, not patent barriers.

A commercially differentiated formulation could include a long-acting injectable, transdermal delivery system, liquid oral formulation or a combination product. Such products would require separate development, regulatory review and potentially new intellectual-property protection. No such product currently defines the Cogentin market.

What patent litigation affects Cogentin?

Cogentin does not have a high-profile current patent litigation profile comparable to major branded drugs. The absence of active litigation reflects the product’s age, generic availability and low expected return from enforcement.

Litigation risk is more likely to arise from:

• Generic manufacturing compliance
• Product liability claims
• Labeling disputes
• Antitrust allegations involving supply or contracting
• False-marking or trademark issues
• Commercial disputes over distribution

Patent litigation is unlikely to be the primary determinant of market share. The commercially relevant legal risk is product quality, especially for injectable supply.

What is the FDA regulatory status of Cogentin?

Cogentin is an FDA-approved prescription drug. Benztropine generic products are regulated through the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference product.

The drug is not a biologic and does not require a biologics license application. Biosimilar competition is therefore irrelevant. The principal regulatory distinction is between:

• Generic oral tablets
• Generic injectable products
• Any future reformulated or extended-release product

The FDA label describes dosing that must be individualized according to indication, response and tolerability. The agency’s labeling also reflects risks from central and peripheral anticholinergic effects.[1]

How strong is the Cogentin patent estate?

The patent estate is weak from a current commercial perspective.

Factor	Assessment
Remaining patent term	None of material commercial significance
Claim breadth	Historical claims are no longer blocking
Formulation protection	Limited or absent for standard presentations
Manufacturing protection	No known strategic barrier
Method-of-use protection	Expired for established indications
Generic vulnerability	High
Litigation leverage	Low
Lifecycle-management potential	Limited without a new formulation

The absence of patent protection does not mean supply is risk-free. A generic market can experience shortages when several suppliers produce a product with low margins and one or more facilities encounter quality problems. That risk is operational rather than intellectual-property driven.

How does Cogentin compare with competing treatments?

Cogentin competes with other treatments for extrapyramidal symptoms, drug-induced parkinsonism and related movement disorders. The relevant comparator depends on the clinical problem.

Treatment	Typical role	Competitive relationship
Benztropine	Drug-induced parkinsonism; acute extrapyramidal symptoms	Direct competitor
Trihexyphenidyl	Parkinsonism and dystonia	Direct pharmacologic competitor
Diphenhydramine	Acute dystonia, often emergency use	Short-term substitute
Amantadine	Parkinsonism and some drug-induced movement symptoms	Alternative mechanism
Propranolol	Akathisia	Treats a different extrapyramidal syndrome
Valbenazine or deutetrabenazine	Tardive dyskinesia	Modern targeted alternative for a distinct condition

Clinical practice can reduce demand for benztropine when clinicians discontinue the causative antipsychotic, lower its dose or switch to a better-tolerated agent. Long-term anticholinergic treatment is also limited by cognitive and peripheral adverse effects, particularly in older adults.

What is the financial trajectory for Cogentin?

Cogentin’s financial trajectory is consistent with a mature generic drug:

• Brand revenue has likely declined as generic substitution expanded.
• Generic volume remains tied to antipsychotic use, hospital formularies and treatment of drug-induced movement disorders.
• Product-level revenue is not separately reported by the brand owner in public filings.
• The market has limited pricing power outside shortage conditions.
• Injectable supply can command greater operational value than tablets but also carries higher manufacturing risk.

A precise Cogentin revenue series cannot be derived from public company filings because manufacturers generally combine benztropine sales with broader generic portfolios. Public disclosure usually reports company-wide pharmaceutical revenue, business segments or product groups rather than individual legacy products.

Who has revenue exposure to Cogentin?

Revenue exposure is distributed across:

• The brand owner or historical marketing authorization holder
• Generic tablet manufacturers
• Generic injectable manufacturers
• Wholesalers and specialty distributors
• Hospitals and institutional pharmacies

The brand’s financial importance to a diversified pharmaceutical company is likely immaterial compared with major patented products. For a small generic manufacturer, however, benztropine can contribute incremental revenue and portfolio utilization, particularly if the company already operates the required oral or sterile manufacturing lines.

What drives future pricing?

The primary pricing drivers are:

1. Number of active suppliers
2. Hospital and pharmacy purchasing contracts
3. Manufacturing interruptions
4. Injectable capacity
5. Reimbursement and generic substitution
6. Demand from psychiatric and neurologic treatment settings

Patent expiry is no longer a future pricing event. The product’s price behavior is determined by generic competition and supply conditions.

What geographic coverage does Cogentin have?

Benztropine has been marketed in the United States for many years and may be available in selected international markets under different brand names or generic labels. Market access varies by jurisdiction because approval status, reimbursement and brand ownership are local matters.

The U.S. market has the clearest generic pathway and the most developed substitution environment. In other countries, benztropine may have a smaller role because treatment standards, antipsychotic utilization and availability of alternative anticholinergics differ.

International commercial value is therefore fragmented. A manufacturer seeking geographic expansion would need to address local registration, pharmacovigilance, pricing controls, distributor access and, for injection, country-specific manufacturing and import requirements.

What generic entry risks exist for Cogentin?

The principal risk is not delayed generic entry. Generic entry has already occurred. The main risks are market erosion and supply volatility.

Commercial risks

• Continued price compression
• Low margins on standard tablets
• Substitution by trihexyphenidyl or newer treatments
• Reduced long-term anticholinergic use
• Institutional preference for alternative suppliers
• Limited ability to differentiate the product

Manufacturing risks

• Sterile injectable production failures
• Batch rejection or recall
• Active pharmaceutical ingredient supply disruption
• Low-volume product discontinuation
• Concentration of supply among few manufacturers

Clinical and regulatory risks

• Increased concern about anticholinergic burden
• Use restrictions in older adults
• Labeling changes related to cognitive or urinary adverse effects
• Reduced use for prophylaxis of extrapyramidal symptoms
• Greater preference for treating the causative antipsychotic exposure

Key Takeaways

• Cogentin is benztropine mesylate, an old anticholinergic used mainly for drug-induced extrapyramidal symptoms and parkinsonism.
• The product has no meaningful remaining regulatory exclusivity.
• Historical compound, formulation and use patents are expired.
• No active patent estate or major Paragraph IV dispute is central to the current market.
• Biosimilar risk does not apply because benztropine is a small-molecule drug.
• Generic competition has shifted value from patent protection to manufacturing reliability, contracts and distribution.
• Brand-level revenue is not separately disclosed in public company reporting.
• Tablets face persistent price pressure; injectable products have greater manufacturing complexity and shortage sensitivity.
• Long-term demand is constrained by anticholinergic safety concerns and competition from alternative treatments.
• The most credible commercial opportunity is reliable generic supply, not premium pricing or lifecycle-based exclusivity.

FAQs

Is Cogentin still a branded-only drug?

No. Benztropine is widely available as a generic. The Cogentin brand may remain available, but generic substitution substantially limits brand pricing power.

Is benztropine a controlled substance?

Benztropine is not generally classified as a controlled substance under the U.S. Controlled Substances Act. It remains a prescription medicine with clinically significant anticholinergic risks.

Can a generic company launch benztropine without a patent license?

A generic company generally does not need a license to expired patents. It must obtain FDA approval, meet manufacturing requirements and comply with applicable labeling and trademark rules.

Does Cogentin have a long-acting injectable version?

Standard Cogentin presentations are oral tablets and injection. No widely established long-acting benztropine formulation defines the current market.

Is Cogentin used for tardive dyskinesia?

Benztropine is not a preferred treatment for tardive dyskinesia and may worsen some tardive movement disorders. FDA-approved vesicular monoamine transporter 2 inhibitors, including valbenazine and deutetrabenazine, target tardive dyskinesia through a different mechanism.[3][4]

References

1. U.S. Food and Drug Administration. (2023). Cogentin (benztropine mesylate) prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2017). FDA approves treatment for tardive dyskinesia. FDA.

4. U.S. Food and Drug Administration. (2018). FDA approves new treatment for adults with tardive dyskinesia. FDA.